Bibliografisk note

Funding Information:
We are most grateful to the patients and their families for participat-ing in the study. We thank the Academy of Finland grant, Academy of Finland Center of Excellence on Translational Cancer Biology, the iCAN Digital Precision Cancer Medicine Flagship, Sigrid Jus?lius Foundation, Cancer Society of Finland, Tekes/Business Finland Salwe program, HUS-EVO, and HUCS Institute for support to this study. We utilized FIMM/HiLife/Biocenter Finland local and national infrastructures (Genome-wide, Bioinformatics, and DDCB National infra-structures) as well as national networks for EU infrastructures BBMRI, ELIXIR, EATRIS, and EU-OPENSCREEN. We thank the excellent staff and resources provided by the FIMM Technology Centre and the FIMM High-Throughput Biomedicine Unit. We thank Minna Suvela, Alun Parsons, and Siv Knaappila for processing patient samples. The authors acknowledge the assistance and support of the personnel at the FIMM Sequencing Unit, especially Pekka Ellonen and Pirkko Mattila. The authors acknowledge the support of personnel at the FIMM High-Throughput Biomedicine Unit: Elina Huovari, Aleksandr Ianevski, Meri Kokkonen, Evgeny Kulesskiy, Sergey Kuznetsov, Karoliina Laamanen, Elina Lehtinen, Piia Mikkonen, Maria Nurmi, Katja N?rhi, Katja Suomi, and Sanna Timonen. D. Malani received personal funding support from the Finnish Cultural Foundation, Blood Disease Research Foundation, Finnish Hematology Association, K. Albin Johansson Foundation, Paivikki ja Sakari Sohlberg Foundation, Maud Kuistila Memorial Foundation, and Helsinki Biomedicum foundation to support this research. M. Helles?y and B.T. Gjertsen received funding from The Norwegian Cancer Society and Helse Vest Health Trust. A. Kumar received an EMBO short-term lab visit fellowship for this study. S. Mustjoki received funding from European Research Council (M-IMM project), Academy of Finland, Cancer Society of Finland, and Sigrid Jus?lius Foundation. T. Aittokallio received funding from Academy of Finland (grants 292611, 310507 and 313267), Cancer Society of Finland, and Sigrid Jus?lius Foundation. K. Wennerberg received funding from Novo Nordisk Foundation (Grant Number NNF17CC0027852). M. Kontro received a University of Helsinki Early Career Grant. C.A. Heckman received funding from the Sigrid Jus?lius Foundation, Cancer Society of Finland, and Academy of Finland (grants 1320185 and 334781). O. Kallioniemi received support from Academy of Finland (259777, 278741, 271845, and 333050), Cancer Society of Finland (120089, 140114, 160080, 170112, and 190116) and Sigrid Jus?lius Foundation, Knut and Alice Wallenberg Foundation (KAW; 2015.0291), Swedish Foundation for Strategic Research (SSF; SB16-0058), VR environment grant (2017-06095), and Vinnova (2018-03338).

Publisher Copyright:
© 2021 The Authors; Published by the American Association for Cancer Research.